Drugs / MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04252118 | Jan → Dec 2020 | COVID-19 | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04252118 ↗ |
| Modality | Cell therapy | “Mesenchymal Stem Cells (MSCs) therapy” NCT04252118 ↗ |
| Route | Intravenous | “MSCs intravenously” NCT04252118 ↗ |